Cargando…

Ologen implant versus mitomycin-C for trabeculectomy: A meta-analysis

AIM: To evaluate the efficacy and safety of trabeculectomy (Trab) with mitomycin-C (MMC) versus Trab with implant. METHODS: Studies published in different languages were retrieved by systematically searching Embase, PubMed, Cochrane library, China Biology Medicine disc, and Google Scholar from 1966...

Descripción completa

Detalles Bibliográficos
Autores principales: Song, De-Sheng, Qian, Jing, Chen, Zhi-Jun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6636945/
https://www.ncbi.nlm.nih.gov/pubmed/31232951
http://dx.doi.org/10.1097/MD.0000000000016094
_version_ 1783436145357488128
author Song, De-Sheng
Qian, Jing
Chen, Zhi-Jun
author_facet Song, De-Sheng
Qian, Jing
Chen, Zhi-Jun
author_sort Song, De-Sheng
collection PubMed
description AIM: To evaluate the efficacy and safety of trabeculectomy (Trab) with mitomycin-C (MMC) versus Trab with implant. METHODS: Studies published in different languages were retrieved by systematically searching Embase, PubMed, Cochrane library, China Biology Medicine disc, and Google Scholar from 1966 to April 2018, as well as manually examining the references of the original articles. The outcome measures of efficacy covered intraocular pressure, glaucoma medications reductions, and success rate. Safety evaluation was measured by relative ratio of complications. RESULTS: A total of 11 studies involving 443 participants were covered in this meta-analysis. The weighted mean difference (WMD) in the percentage of intraocular pressure (IOP) reduction (IOPR%) comparing Ologen group with MMC group was −3.69 (95% CI: −6.70 to −0.68) at 1 month, −2.69 (−5.17 to −0.21) at 3 months, −3.67 (−6.09 to −1.25)at 6 months, −3.24 (−6.08 to −0.41) at 12 months, 1.24 (−9.43 to 11.90) at 24 months, and 1.10 (−10.11 to 12.31) at 60 months, which showed that there was statistically significant difference at 1,3, 6, and12 months after the surgery. A significantly higher incidence of postsurgery hypotony (0.64 (95% Cl: 0.42 to 0.98)) and suture lysis (0.30 (95% CI: 0.10–0.93)) was observed in MMC group. However, there was no significant difference in the reduction in glaucoma medications, success rate, and incidence of other complications. Trab with 0.2 mg/mL MMC presented higher rates of complete success compared with Trab with 0.4 mg/mL MMC (P = .01). CONCLUSION: Trab with MMC was associated with a higher IOP-lowering efficacy and a higher incidence of postsurgery hypotony and suture lysis in contrast to that of Trab with Ologen.
format Online
Article
Text
id pubmed-6636945
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Wolters Kluwer Health
record_format MEDLINE/PubMed
spelling pubmed-66369452019-08-01 Ologen implant versus mitomycin-C for trabeculectomy: A meta-analysis Song, De-Sheng Qian, Jing Chen, Zhi-Jun Medicine (Baltimore) Research Article AIM: To evaluate the efficacy and safety of trabeculectomy (Trab) with mitomycin-C (MMC) versus Trab with implant. METHODS: Studies published in different languages were retrieved by systematically searching Embase, PubMed, Cochrane library, China Biology Medicine disc, and Google Scholar from 1966 to April 2018, as well as manually examining the references of the original articles. The outcome measures of efficacy covered intraocular pressure, glaucoma medications reductions, and success rate. Safety evaluation was measured by relative ratio of complications. RESULTS: A total of 11 studies involving 443 participants were covered in this meta-analysis. The weighted mean difference (WMD) in the percentage of intraocular pressure (IOP) reduction (IOPR%) comparing Ologen group with MMC group was −3.69 (95% CI: −6.70 to −0.68) at 1 month, −2.69 (−5.17 to −0.21) at 3 months, −3.67 (−6.09 to −1.25)at 6 months, −3.24 (−6.08 to −0.41) at 12 months, 1.24 (−9.43 to 11.90) at 24 months, and 1.10 (−10.11 to 12.31) at 60 months, which showed that there was statistically significant difference at 1,3, 6, and12 months after the surgery. A significantly higher incidence of postsurgery hypotony (0.64 (95% Cl: 0.42 to 0.98)) and suture lysis (0.30 (95% CI: 0.10–0.93)) was observed in MMC group. However, there was no significant difference in the reduction in glaucoma medications, success rate, and incidence of other complications. Trab with 0.2 mg/mL MMC presented higher rates of complete success compared with Trab with 0.4 mg/mL MMC (P = .01). CONCLUSION: Trab with MMC was associated with a higher IOP-lowering efficacy and a higher incidence of postsurgery hypotony and suture lysis in contrast to that of Trab with Ologen. Wolters Kluwer Health 2019-06-21 /pmc/articles/PMC6636945/ /pubmed/31232951 http://dx.doi.org/10.1097/MD.0000000000016094 Text en Copyright © 2019 the Author(s). Published by Wolters Kluwer Health, Inc. http://creativecommons.org/licenses/by-nc/4.0 This is an open access article distributed under the terms of the Creative Commons Attribution-Non Commercial License 4.0 (CCBY-NC), where it is permissible to download, share, remix, transform, and buildup the work provided it is properly cited. The work cannot be used commercially without permission from the journal. http://creativecommons.org/licenses/by-nc/4.0
spellingShingle Research Article
Song, De-Sheng
Qian, Jing
Chen, Zhi-Jun
Ologen implant versus mitomycin-C for trabeculectomy: A meta-analysis
title Ologen implant versus mitomycin-C for trabeculectomy: A meta-analysis
title_full Ologen implant versus mitomycin-C for trabeculectomy: A meta-analysis
title_fullStr Ologen implant versus mitomycin-C for trabeculectomy: A meta-analysis
title_full_unstemmed Ologen implant versus mitomycin-C for trabeculectomy: A meta-analysis
title_short Ologen implant versus mitomycin-C for trabeculectomy: A meta-analysis
title_sort ologen implant versus mitomycin-c for trabeculectomy: a meta-analysis
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6636945/
https://www.ncbi.nlm.nih.gov/pubmed/31232951
http://dx.doi.org/10.1097/MD.0000000000016094
work_keys_str_mv AT songdesheng ologenimplantversusmitomycincfortrabeculectomyametaanalysis
AT qianjing ologenimplantversusmitomycincfortrabeculectomyametaanalysis
AT chenzhijun ologenimplantversusmitomycincfortrabeculectomyametaanalysis